TGF-β1 Protein Expression in Non-Small Cell Lung Cancers is Correlated with Prognosis |
Huang, Ai-Li
(Department of Pathology, Nanfang Hospital, Southern Medical University)
Liu, Shu-Guang (Department of Pathology, Nanfang Hospital, Southern Medical University) Qi, Wen-Juan (Department of Pathology, Nanfang Hospital, Southern Medical University) Zhao, Yun-Fei (Department of Pathology, Nanfang Hospital, Southern Medical University) Li, Yu-Mei (Department of Pathology, Nanfang Hospital, Southern Medical University) Lei, Bin (Department of Pathology, Nanfang Hospital, Southern Medical University) Sheng, Wen-Jie (Department of Pathology, Nanfang Hospital, Southern Medical University) Shen, Hong (Department of Pathology, Nanfang Hospital, Southern Medical University) |
1 | Assoian RK, Komoriya A, Meyers CA, et al (1983). Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem, 258, 7155-60. |
2 | Bai X, Shen H, Zhou C, et al (2009). Expression of thyroid transcription factor-l (TTF-1)in lung carcinomas and its correlations with apoptosis and angiogenesis. Clin Oncol Cancer Res, 6, 16-20. |
3 | Blobe GC, Schiemann WP, Lodish HF (2000). Role of transforming growth factor beta in human disease. N Engl J Med, 342, 1350-8. DOI ScienceOn |
4 | Boyd FT, Massague J (1989). Transforming growth factorbeta inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem, 264, 2272-8. |
5 | Chen XF, Zhang HJ, Wang HB, et al (2012). Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep, 39, 3549-56. DOI |
6 | Grady WM, Rajput A, Myeroff L, et al (1998). Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res, 58, 3101-4. |
7 | Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29. DOI ScienceOn |
8 | Ellermeier J, Wei J, Duewell P, et al (2013). Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer. Cancer Res, 73, 1709-20. DOI |
9 | Furuta K, Misao S, Takahashi K, et al (1999). Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma. Int J Cancer, 81, 851-3. DOI |
10 | Tripsianis G, Papadopoulou E, Romanidis K, et al (2013). Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF- and TGF-. Asian Pac J Cancer Prev, 14, 6813-20. DOI ScienceOn |
11 | Janda E, Lehmann K, Killisch I, et al (2002). Ras and TGF cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol, 156, 299-313. DOI ScienceOn |
12 | Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics, 2007. CA Cancer J Clin, 57, 43-66. DOI ScienceOn |
13 | Jennings MT, Pietenpol JA (1998). The role of transforming growth factor beta in glioma progression. J Neurooncol, 36, 123-40. DOI |
14 | Kasai H, Allen JT, Mason RM, et al (2005). TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res, 6, 56. DOI ScienceOn |
15 | Kim WS, Park C, Jung YS, et al (1999). Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res, 19, 301-6. |
16 | Ma J, Gao H-M, Hua X, et al (2014). Role of TGF- in human colorectal cancer and effects after cantharidinate intervention. Asian Pac J Cancer Prev, 15, 4045-8. DOI |
17 | Markowitz S, Wang J, Myeroff L, et al (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science, 268, 1336-8. DOI |
18 | Lei B, Liu S, Qi WJ, et al (2013). PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression. Histopathology, 63, 696-703. |
19 | Luwor RB, Kaye, AH, Zhu HJ (2008). Transforming growth factor-beta (TGF-beta) and brain tumours. J Clin Neurosci, 15, 845-55. DOI |
20 | Rich J, Borton A, Wang X (2001). Transforming growth factorbeta signaling in cancer. Microsc Res Tech, 52, 363-73. DOI ScienceOn |
21 | Siegel PM, Massague J (2003). Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer, 3, 807-21. DOI ScienceOn |
22 | Shen H, Lu Y (1993). Study on quantitative method of immunochemical staining. J Biomed Eng, 10, 281-4. |
23 | Shen H (1994). Study on quantitative method of intensity of immunohistochemical staining (II). J Cell Mol Immunol, 10, 33-5. |
24 | Shen H (1995). Study on quantitative method of immunochemical staining (III). Chin J Histochem Cytochem, 4, 89-92. |
25 | Takanami I, Imamura T, Hashizume T, et al (1994). Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol, 47, 1098-100. DOI ScienceOn |
26 | Wiedmann MW, Caca K (2005). Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets, 5, 171-93. DOI |
27 | Takanami I, Tanaka F, Hashizume T, et al (1997). Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J Surg Oncol, 64, 262-7. DOI ScienceOn |
28 | Xu XY, Lin N, Li YM, et al (2013). Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer. Pathol Res Pract, 209, 345-52. DOI |
29 | Wan L, Li X, Shen H, et al (2013). Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics. Clin Transl Oncol, 15, 132-8. DOI |
30 | Xu CC, Wu LM, Sun W, et al (2011). Effects of TGF-beta signaling blockade on human A549 lung adenocarcinoma cell lines. Mol Med Rep, 4, 1007-15. |
31 | Xue YJ, Lu Q, Sun ZX (2011). CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol, 28, 1363-72. DOI |
32 | Yanagisawa K, Uchida K, Nagatake M, et al (2000). Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers. Oncogene, 19, 2305-11. DOI |